A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799.
Both Ro 03-8799 and misonidazole were administered to six patients before tumour sampling. Using similar doses, tumour concentrations of Ro 03-8799 were approximately double those of misonidazole. Examination of the data with regard to the relative sensitising efficiencies of these two compounds gives us, as a conservative estimate, a factor of 1.6 in favour of Ro 03-8799. From these observations it is predicted that, when given with radiotherapy in a 25-fraction course Ro 03-8799, is likely to be at least five times more effective as a hypoxic cell sensitiser than misonidazole.
D000328:Adult; D000368:Aged; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000532:radiotherapy; D006224:Cricetinae; D003412:Cricetulus; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000378:metabolism* / Q000532:radiotherapy; D051379:Mice; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage* / Q000378:metabolism; D009593:Nitroimidazoles / Q000008:administration & dosage* / Q000378:metabolism; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000532:radiotherapy
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole; D008920:Misonidazole